Source: CNBC
“Novo Nordisk filed a lawsuit against Eli Lilly, alleging that its advertising campaigns for its blockbuster obesity and diabetes drugs are designed to mislead consumers about their superior efficacy relative to the Danish drugmaker’s rival injections. Novo Nordisk is specifically taking issue with nationwide ads that cite what it called ‘outdated’ clinical trials to compare the highest doses of Lilly’s medicines to lower doses of Novo’s drugs. Novo asked the court to permanently stop Lilly from running the ads and require the drugmaker to issue corrective advertising.” (07/21/26)
https://www.cnbc.com/2026/07/21/novo-nordisk-sues-eli-lilly-glp-1-ads.html